Integrating Targeted Therapies into AML Frontline Therapy: Who Gets What and What Does the Future Hold?

Cancers (Basel) · 2026 · PMC13025187 · PMID 41899634

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the FLT3 m subgroup ( n = 66), oral azacitidine improved relapse-free survival (RFS) and showed a trend toward improved OS [ 15 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.